Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance HemodialysisYoshihiro Tominaga, Tetsuo Shoji, Masaaki Inaba et al.|JAMA|2018Cited by 91
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial)Hideki Kato, Ichiei Narita, Masaomi Nangaku et al.|Clinical and Experimental Nephrology|2017Cited by 20
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN studyIchiei Narita, Yoshiharu Tsubakihara, Tadashi Sofue et al.|PLoS ONE|2022Cited by 20
Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in JapanTerumasa Hayashi, Ichiei Narita, Hideki Kato et al.|Clinical and Experimental Nephrology|2020Cited by 15